Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
9(64%)
Results Posted
150%(3 trials)

Phase Distribution

Ph phase_3
1
7%
Ph phase_1
2
14%
Ph phase_2
11
79%

Phase Distribution

2

Early Stage

11

Mid Stage

1

Late Stage

Phase Distribution14 total trials
Phase 1Safety & dosage
2(14.3%)
Phase 2Efficacy & side effects
11(78.6%)
Phase 3Large-scale testing
1(7.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

9

trials recruiting

Total Trials

14

all time

Status Distribution
Active(10)
Completed(2)
Other(2)

Detailed Status

Recruiting6
Active, not recruiting3
unknown2
Completed2
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
14
Active
9
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (14.3%)
Phase 211 (78.6%)
Phase 31 (7.1%)

Trials by Status

unknown214%
not_yet_recruiting17%
completed214%
active_not_recruiting321%
recruiting643%

Recent Activity

9 active trials
Showing 5 of 14
active_not_recruitingphase_2

Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma

NCT04151667
active_not_recruitingphase_2

Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM

NCT04009109
completedphase_2

Study of Daratumumab in Patients With Mild to Moderate Alzheimer's Disease

NCT04070378
recruitingphase_1

Subcutaneous Daratumumab Administration in the Thigh Vs Abdomen in Plasma Cell Disorders

NCT07075510
not_yet_recruitingphase_2

Daratumumab for T Cell ALL With MRD-positive After Standard Chemotherapy

NCT06570915
View all 14 trials

Clinical Trials (14)

Showing 14 of 14 trials
NCT04151667Phase 2

Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma

Active Not Recruiting
NCT04009109Phase 2

Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM

Active Not Recruiting
NCT04070378Phase 2

Study of Daratumumab in Patients With Mild to Moderate Alzheimer's Disease

Completed
NCT07075510Phase 1

Subcutaneous Daratumumab Administration in the Thigh Vs Abdomen in Plasma Cell Disorders

Recruiting
NCT06570915Phase 2

Daratumumab for T Cell ALL With MRD-positive After Standard Chemotherapy

Not Yet Recruiting
NCT06838962Phase 2

Anti-CD38 Antibody Treating Children With Primary Immune Thrombocytopenia (ITP)

Recruiting
NCT07063199Phase 2

Anti-CD38 Antibody Treating Elderly Patients With Primary Immune Thrombocytopenia (ITP)

Recruiting
NCT05451771Phase 1

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

Recruiting
NCT07021677Phase 2

Use of a New Medicine "Daratumumab" to Treat Left-over Cancer in a Blood Cancer Called "T Acute Lymphoblastic Leukemia"

Recruiting
NCT05562882Phase 2

A Clinical Trial to Assess Safety and Efficacy of Daratumumab in the Treatment of Primary Immune Thrombocytopenia

Active Not Recruiting
NCT06187441Phase 3

FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM)

Recruiting
NCT04703621Phase 2

The DART Study- Daratumumab Treatment in ITP

Unknown
NCT04396496Phase 2

Treatment of POEMS Syndrome With Daratumumab

Completed
NCT04810754Phase 2

An Open Label Study to Evaluate Daratumumab in Participants With Moderate to Severe Systemic Lupus Erythematosus

Unknown

All 14 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
14